News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
275,001 Results
Type
Article (9630)
Company Profile (20)
Press Release (265351)
Multimedia
Podcasts (7)
Webinars (2)
Section
Business (76122)
Career Advice (336)
Deals (16695)
Drug Delivery (39)
Drug Development (40985)
Employer Resources (27)
FDA (7708)
Job Trends (5682)
News (143521)
Policy (15199)
Tag
2024 BioMidwest Digital (1)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
Academia (709)
Accelerated approval (2)
Adcomms (7)
Allergies (42)
Alliances (17859)
ALS (46)
Alzheimer's disease (669)
Antibody-drug conjugate (ADC) (44)
Approvals (7755)
Artificial intelligence (108)
Autoimmune disease (11)
Automation (5)
Bankruptcy (173)
Best Places to Work (5198)
BIOSECURE Act (2)
Biosimilars (56)
Biotechnology (23)
Bladder cancer (50)
Brain cancer (16)
Breast cancer (115)
Cancer (1204)
Cardiovascular disease (75)
Career advice (297)
Career pathing (4)
CAR-T (91)
Cell therapy (226)
Cervical cancer (13)
Clinical research (34644)
Collaboration (346)
Compensation (99)
Complete response letters (10)
COVID-19 (981)
CRISPR (19)
C-suite (82)
Cystic fibrosis (39)
Data (1359)
Denatured (4)
Depression (19)
Diabetes (123)
Diagnostics (2539)
Digital health (6)
Diversity (2)
Diversity, equity & inclusion (10)
Drug discovery (56)
Drug pricing (56)
Drug shortages (17)
Duchenne muscular dystrophy (46)
Earnings (39217)
Editorial (14)
Employer branding (1)
Employer resources (22)
Events (36569)
Executive appointments (275)
FDA (8407)
Featured Employer (3)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (303)
Gene editing (48)
Generative AI (10)
Gene therapy (136)
GLP-1 (224)
Government (2354)
Grass and pollen (3)
Guidances (36)
Healthcare (7418)
Huntington's disease (5)
IgA nephropathy (14)
Immunology and inflammation (44)
Indications (20)
Infectious disease (1054)
Inflammatory bowel disease (73)
Inflation Reduction Act (6)
Influenza (26)
Intellectual property (56)
Interviews (50)
IPO (8799)
IRA (20)
Job creations (797)
Job search strategy (259)
Kidney cancer (8)
Labor market (5)
Layoffs (70)
Leadership (3)
Legal (2663)
Liver cancer (40)
Lung cancer (178)
Lymphoma (86)
Machine learning (1)
Management (8)
Manufacturing (123)
MASH (37)
Medical device (5610)
Medtech (5611)
Mergers & acquisitions (8250)
Metabolic disorders (305)
Multiple sclerosis (46)
NASH (8)
Neurodegenerative disease (29)
Neuropsychiatric disorders (5)
Neuroscience (912)
NextGen: Class of 2025 (1807)
Non-profit (1107)
Northern California (1313)
Now hiring (1)
Obesity (154)
Opinion (83)
Ovarian cancer (55)
Pain (39)
Pancreatic cancer (46)
Parkinson's disease (72)
Partnered (5)
Patents (148)
Patient recruitment (68)
Peanut (22)
People (17941)
Pharmaceutical (8)
Pharmacy benefit managers (8)
Phase I (10633)
Phase II (15094)
Phase III (11885)
Pipeline (786)
Policy (40)
Postmarket research (988)
Preclinical (3903)
Press Release (11)
Prostate cancer (59)
Psychedelics (12)
Radiopharmaceuticals (128)
Rare diseases (163)
Real estate (1344)
Recruiting (8)
Regulatory (11197)
Reports (18)
Research institute (667)
Resumes & cover letters (42)
Rett syndrome (4)
RNA editing (2)
RSV (21)
Schizophrenia (33)
Series A (51)
Series B (35)
Service/supplier (4)
Sickle cell disease (23)
Southern California (1153)
Special edition (3)
Spinal muscular atrophy (40)
Sponsored (14)
Startups (857)
Stomach cancer (7)
Supply chain (26)
Tariffs (11)
The Weekly (2)
United States (11274)
Vaccines (242)
Venture capitalists (7)
Weight loss (89)
Women's health (13)
Worklife (4)
Date
Today (75)
Last 7 days (294)
Last 30 days (1300)
Last 365 days (17310)
2025 (5026)
2024 (18548)
2023 (21073)
2022 (27932)
2021 (29285)
2020 (26574)
2019 (17917)
2018 (13613)
2017 (13785)
2016 (11723)
2015 (14339)
2014 (9843)
2013 (7270)
2012 (7557)
2011 (8176)
2010 (7566)
Location
Africa (239)
Alabama (17)
Alaska (3)
Arizona (59)
Arkansas (3)
Asia (19368)
Australia (5028)
California (2972)
Canada (1534)
China (252)
Colorado (125)
Connecticut (163)
Delaware (64)
Europe (32893)
Florida (483)
Georgia (96)
Idaho (10)
Illinois (219)
India (22)
Indiana (138)
Iowa (4)
Japan (94)
Kansas (17)
Kentucky (5)
Louisiana (5)
Maine (40)
Maryland (378)
Massachusetts (2208)
Michigan (55)
Minnesota (114)
Missouri (45)
Montana (11)
Nebraska (8)
Nevada (40)
New Hampshire (41)
New Jersey (1059)
New Mexico (3)
New York (958)
North Carolina (414)
North Dakota (3)
Northern California (1313)
Ohio (71)
Oklahoma (1)
Oregon (11)
Pennsylvania (711)
Puerto Rico (6)
Rhode Island (9)
South America (393)
South Carolina (11)
Southern California (1153)
Tennessee (45)
Texas (448)
Utah (70)
Virginia (77)
Washington D.C. (19)
Washington State (353)
West Virginia (2)
Wisconsin (12)
275,001 Results for "teva canada limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Business
Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry
Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry.
February 7, 2024
·
4 min read
Press Releases
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
April 7, 2025
·
8 min read
Earnings
Teva Reports Strong Generics Demand in Q3, Expects Higher 2024 Revenue
Driven by copycat versions of Bristol Myers Squibb’s Revlimid and Novo Nordisk’s Victoza, Teva’s generics business was again a top-performer in the third quarter, with U.S. sales growing 30% and bringing in $1.1 billion in sales.
November 7, 2024
·
2 min read
·
Tristan Manalac
Legal
Teva to Pay $450M in Settlement With DOJ Over Kickback and Price-Fixing Allegations
The U.S. Department of Justice alleged that Teva violated the Anti-Kickback Statute and the False Claims Act. The payment is in addition to the criminal penalty paid by Teva USA under its deferred prosecution agreement.
October 11, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Teva Releases Q1 2025 Aide Memoire
March 28, 2025
·
2 min read
Multiple sclerosis
FDA Tacks Boxed Warning on Teva’s Copaxone, Other MS Drugs
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since December 1996 and six patient deaths.
January 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
April 8, 2025
·
17 min read
Press Releases
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
February 24, 2025
·
21 min read
Business
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
Teva Pharmaceutical Industries Ltd. today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024.
May 15, 2024
·
7 min read
1 of 27,501
Next
